Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Recombinant Human Serum Albumin Is Animal-Free

By Labmedica International staff writers
Posted on 15 Dec 2011
Print article
A company that develops, manufactures, and markets a portfolio of products used in cell culture, diagnostics, and bioproduction has developed recombinant human serum albumin that is completely animal-free.

Animal-derived media components carry safety concerns involving the risk of viral and prion contamination. As a result, regulatory bodies in the United States, Europe, and Japan have discouraged the use of these components in biomanufacturing. In addition to safety concerns, animal components frequently have high batch-to-batch variation, which leads to unpredictable manufacturing results.

InVitria (Fort Collins, CO, USA) was awarded a USD 725,000 Phase II, Small Business Innovation Research (SBIR) Grant to broaden the applications for InVitria’s recombinant human serum albumin product Cellastim.

The Phase II grant was awarded in 2009 by the National Institutes of Health (NIH; Bethesda, MD, USA) as a two-year project, which was successfully completed on time in 2011. “We are delighted that the objectives of the grant were achieved. The team exceeded those objectives and also implemented current Good Manufacturing Process (cGMP) quality standards for manufacturing recombinant human serum albumin,” said Scott Deeter, president of InVitria.
InVitria is a Division of Ventria Bioscience, the developer of the ExpressTec biomanufacturing system. ExpressTec is the first biomanufacturing system to commercialize recombinant protein manufacturing utilizing plants as the host. InVitria’s product line consists of completely animal-free cell culture media supplements and reagents that are distributed globally by leading distributors in life sciences and cell culture media.

Related Links:
InVitria
National Institutes of Health


Print article
Abbott Diagnostics

Channels

Industry News

view channel

Global In Vitro Diagnostic Test Market Worth USD 60 Billion

The global in vitro diagnostic (IVD) test market is currently worth USD 60.5 billion and will continue to grow, though a moderate and gradual change is likely to be witnessed over the next five to ten years, as more opportunities are created in novel tests and growing regions, while the traditional categories and reliable... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.